

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/530,176
Confirmation Number	8060
Filing Date	March 9, 2006
First Named Inventor	Graham Edmund KELLY
Art Unit	1612
Examiner Name	Benjamin J PACKARD
Attorney Docket Number	Q86664

## U.S. PATENTS

Examiner Initials*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

## U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initials*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No	Foreign Document Number <sup>2</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1.	5-070348	JP	A	1993-03-23	KUREHA CHEMICAL IND CO LTD		Abstract

## NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T <sup>5</sup>
	1.	H. ADLERCREUTZ, et al., "Determination of Urinary Lignans and Phytoestrogen Metabolites, Potential Antiestrogens and Anticarcinogens, In Urine of Women on Various Habitual Diets", Proceedings of the XII International Study Group for Steroid Hormones, (Rome, 2-4 December 1985), pages 791-797	
	2.	BEVERLY A. TEICHER, et al., "Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma", Cancer Chemother Pharmacol (1996) 38: 169-177	
	3.	SARA CALTAGIRONE, et al., "Flavonoids Apigenin and Quercetin Inhibit Melanoma Growth and Metastatic Potential", Int. J. Cancer, 87, (2000), pages 555-600	
	4.	HILARY J. CROSS, et al., "Effect of Quercetin on the Genotoxic Potential of Cisplatin", Int. J. Cancer: 66 (1996), pages 404-408	
	5.	JOHANN HOFMANN, et al., "Enhancement of the Antiproliferative Activity of Cis-Diamminedichloroplatinum(II) By Quercetin", Int. J. Cancer, 45, (1990), pages 536-539	
	6.	MORAG C.E. MCFADYEN, et al., "Cyclochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance", Biochemical Pharmacology 62 (2001), pages 207-212	
	7.	YASUYUKI SADZUKA, et al., "Efficacies of tea components on doxorubicin induced antitumor activity and reversal of multidrug resistance", Toxicology Letter 114, (2000) pages 155-162	
	8.	AGNIESZKA SWIINSKA, et al., "Potentiation of the Antiproliferative Effect In Vitro of Doxorubicin, Cisplatin and Genistein by New Analogues of Vitamin D", Anticancer Research 21: (2001), pages 1925-1930	
	9.	JUSTYNA STAWINSKA, et al., "The reactivity of cis-platin. Spectroscopic properties of products isolated from the (cis-Pt(NH <sub>3</sub> ) <sub>2</sub> Cl <sub>2</sub> -quercetin) and [cis-Pt(NH <sub>3</sub> ) <sub>2</sub> Cl <sub>2</sub> -Cr <sup>3+</sup> -quercetin] systems," Transition Metal Chemistry 26: 2001, pages 153-159	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 601.34. 2. Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5. Applicant is to place a check mark here if English language translation is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/530,176
Confirmation Number	8060
Filing Date	March 9, 2006
First Named Inventor	Graham Edmund KELLY
Art Unit	1612
Examiner Name	Benjamin J PACKARD
Attorney Docket Number	Q86664

## NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T <sup>5</sup>
	10.	YUICHIRO TAKEDA, et al, "Reversal of Multidrug Resistance By Tyrosine-Kinase Inhibitors in a Non-P-Glycoprotein-Mediated Multidrug-Resistant Cell Line", Int. J. Cancer: 57, (1994), pages 229-239	
	11.	ELZBIETA ZYNER, et al, "Platinum(II) and Palladium(II) N,O-Chelates With Substituted Flavanone Containing Ligands", Drug Research, Vol. 56, No. 2, 1999, pages 159-167	
	12.	Database Medline - XP008099672 & Am J Resp Cell 1997, 17, 51-59	

## EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.